Valued at USD 312.62 million in 2025, the Residual DNA Testing Market is expected to reach USD 329.66 million in 2026 and USD 519.69 million by 2034, expanding at a CAGR of 5.9% during the forecast period 2026–2034. Rising biologics manufacturing and vaccine manufacturing, along with increasing regulatory focus on product safety, are the principal drivers. North America led in 2025 with a 43.72% share. Key players include Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, Danaher Corporation, Bio-Rad Laboratories Inc., Agilent Technologies Inc., PerkinElmer Inc., Charles River Laboratories International Inc., Lonza Group AG, SGS SA, Eurofins Scientific SE, and QIAGEN N.V. This article examines application and outsourcing trends in the Residual DNA Testing Market.

Application Demand: Biologics, Vaccines and Advanced Therapies

Biologics dominated applications in 2025, driven by rising production of monoclonal antibodies and recombinant proteins, where residual DNA testing is essential for product purity. Expansion of biologics manufacturing raises the need to detect DNA contamination, and testing procedures are integrated throughout the process, from upstream to downstream. Growth in vaccine manufacturing is increasing the need for routine testing, as producers maintain safety and uniformity in large batch production and regulators enforce stringent DNA levels in vaccines. The gene therapy segment is projected to grow at the fastest CAGR owing to increasing development of advanced therapies; high-sensitivity testing is required for complex genetic products, and growth in clinical pipelines supports adoption. Biosimilars complete the application mix alongside biologics, vaccines and gene therapy, while the technology segmentation covers PCR, NGS and ELISA and sample types span raw materials, in-process, final product and fill-finish.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/residual-dna-testing-market

Outsourcing Trends: Contract Research and Manufacturing

CRO services are projected to grow at the fastest CAGR among product and service segments, owing to rising outsourcing of analytical testing as organizations optimize costs and efficiency; the development of contract testing facilities is helping the segment expand. Among end users, CDMOs are projected to grow fastest owing to rising outsourcing of biopharmaceutical manufacturing and testing, as service providers expand analytical capabilities. Biotech captured the largest end-user share in 2025, and major demand comes from pharmaceutical companies, biotechnology firms and CDMOs. The expansion of CRO services and CDMOs is also increasing competitive intensity, with strategic partnerships and technology advancements supporting market positioning.

Regional Growth Patterns

North America's 43.72% share reflects strong biologics output and strict regulatory standards, with the US accounting for roughly 80% of regional revenue. Europe holds the second-largest share thanks to a robust regulatory environment and rising biologics production. Asia Pacific is projected to grow at a 6.5% CAGR as biologics and vaccine manufacturing expand rapidly, with India and China building biomanufacturing plants and quality control systems, while growth in CDMOs and government support improve testing demand; in May 2025, Gene Solutions collaborated with NEWCL to provide genetic testing solutions in Taiwan using NGS lab services. Latin America and Middle East & Africa show steady growth as healthcare facilities improve and biopharmaceutical investment rises; Brazil and South Africa are improving capacity for vaccine manufacturing and biologics manufacturing.

Technology Trends and Strategic Outlook

The Residual DNA Testing market is evolving due to increased cell and gene therapy usage, stricter regulation and continuing technology advances. The complex nature of modern therapies has increased demand for sensitive DNA testing, and residual DNA regulations have become stricter, strengthening quality control. Automation of testing equipment is increasingly widespread, with high-throughput systems supporting large-scale biologics manufacturing, while AI-based analysis improves speed. Continuous bioprocessing is making real-time DNA tests necessary. The high cost of advanced technologies remains a barrier for small manufacturers, yet the outlook remains strong due to adoption of advanced DNA detection technologies and expansion of biologics pipelines.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market